Sai Life Sciences grows topline by 29% & doubles net profit in FY26

EBITDA up by 56%YoY; Net Profit up by 109%YoY

Hyderabad, May 14, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the fourth quarter and full year ended 31 March 2026.

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of innovation-led outsourcing and supply chain diversification continue to remain strong, and we are well positioned to participate meaningfully in this opportunity."

Mr. Siva Chittor, Chief Financial Officer, Sai Life Sciences Limited added, “FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities.

Financial Performance:

Particulars (₹ crores)	Q4FY26	Q4FY25	YoY%	FY26	FY25	YoY%
Revenue from Operations	602	580	4%	2,192	1,695	29%
EBITDA	189	161	17%	661	425	56%
EBITDA Margin%	31%	28%		30%	25%
PBT	139	119	17%	466	228	104%
PAT *	104	88	18%	355	170	109%
PAT Margin%	17%	15%		16%	10%

    Note: *before exceptional items

Key Highlights

• Growth has been on account of the following factors:
  • Deepening engagement with large pharma
  • Momentum in integrated discovery services
  • Investments in new modalities and next-generation technologies
• Revenue from Operations was ₹2,192 Cr for FY26 compared to ₹1,695 Cr in FY25, an increase of 29%.
• EBITDA stood at ₹661 Cr for FY26 compared to ₹425 Cr in FY25, an increase of 56%.
• PAT stood at ₹355 Cr for FY26 compared to ₹170 Cr in FY25, an increase of 109%.
• Incurred Capex of ₹633 Cr

Earnings Call:

Sai Life Sciences will conduct earnings call at 4.00 PM (IST) on 15 May 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date	May 15, 2026
Time	04:00 PM – 5:00 PM (IST)
Dial-in Number	+91 22 6280 1107, +91 22 7115 8008
International Toll Free	USA: 18667462133 | UK: 08081011573 | Singapore: 8001012045 | Hong Kong: 800964448
Pre-Registration Facility	Click here

About Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE)

Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning discovery, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.